These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 32279037)
1. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Das D; Xie L; Wang J; Shi J; Hong J Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037 [TBL] [Abstract][Full Text] [Related]
2. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC). Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890 [TBL] [Abstract][Full Text] [Related]
4. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1. Das D; Xie L; Wang J; Xu X; Zhang Z; Shi J; Le X; Hong J Bioorg Med Chem Lett; 2019 Feb; 29(4):591-596. PubMed ID: 30600209 [TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective EGFR Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation. Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841 [TBL] [Abstract][Full Text] [Related]
10. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers. Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151 [TBL] [Abstract][Full Text] [Related]
11. Novel 4-arylaminoquinazolines bearing Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043 [TBL] [Abstract][Full Text] [Related]
12. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. Xie H; Lin L; Tong L; Jiang Y; Zheng M; Chen Z; Jiang X; Zhang X; Ren X; Qu W; Yang Y; Wan H; Chen Y; Zuo J; Jiang H; Geng M; Ding J PLoS One; 2011; 6(7):e21487. PubMed ID: 21789172 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor. Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904 [TBL] [Abstract][Full Text] [Related]
16. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049 [TBL] [Abstract][Full Text] [Related]
17. Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation. Yao H; Ren Y; Wu F; Liu J; Li J; Cao L; Yan M; Li X Eur J Med Chem; 2024 Sep; 275():116590. PubMed ID: 38908104 [TBL] [Abstract][Full Text] [Related]
18. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Li D; Ambrogio L; Shimamura T; Kubo S; Takahashi M; Chirieac LR; Padera RF; Shapiro GI; Baum A; Himmelsbach F; Rettig WJ; Meyerson M; Solca F; Greulich H; Wong KK Oncogene; 2008 Aug; 27(34):4702-11. PubMed ID: 18408761 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. Zhou P; Chen G; Gao M; Wu J Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]